RTI Biologics (RTIX) Cuts FY10 Outlook

September 7, 2010 4:04 PM EDT Send to a Friend
Get Alerts RTIX Hot Sheet
Trade RTIX Now!
Join SI Premium – FREE
RTI Biologics (Nasdaq: RTIX) lowers its FY10 EPS guidance from 15-17c to 10-12c and its sales guidance from $174.5-$177.5 million to $165-$168 million. The Street is currently looking for EPS of 11c on sales of $168.09 million.

The guidance comes amid a distribution pact with Zimmer Dental.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Guidance

Add Your Comment